Indications: For diabetes.

Specification: 3ml:300 units (refill); 3ml:300 units (special charge).

Dosage and Administration:

1. If necessary, it may be administered immediately after a meal.

2. The dosage of this product varies from person to person and should be determined by a physician based on the patient's condition. It should normally be combined with at least once daily intermediate-acting insulin or long-acting insulin. The insulin requirement is usually 0.5-1.0 U per kilogram of body weight per day. 50%-70% of the insulin requirement is provided by this product and the rest is provided by intermediate-acting or long-acting insulin in treatments associated with meals.

3. This product may be given as a subcutaneous injection in the abdomen, thighs, deltoid muscles of the upper arms, or buttocks. To prevent fat atrophy, the injection site should be rotated within the injection area. After subcutaneous injection in the abdomen, the effect takes place within 10-20 minutes. The maximum duration of action is 1-3 hours after injection and the hypoglycemic effect lasts for 3-5 hours. The duration of the hypoglycemic effect of all insulins is influenced by a number of factors such as: the dose of insulin injected, the site of injection, the rate of blood flow, body temperature, and the intensity of physical activity. All insulins are absorbed more rapidly when administered subcutaneously from the abdomen than from other injection sites. However, this product works faster than soluble human insulin regardless of the site of injection. If necessary, this product may be administered intravenously by trained medical personnel.

4. This product may be used in insulin pumps for continuous subcutaneous insulin infusion therapy (CSII), which should be performed on the abdominal wall with rotation of injection sites.

5. When using an insulin pump to infuse this product, it should not be mixed with other insulins.

6. patients receiving continuous subcutaneous insulin infusion therapy should receive detailed instructions on this subject, including how to use the insulin pump and the use of appropriate reservoirs and tubing. Infusion devices (tubing and needles) must be changed according to the relevant requirements in the instructions for the infusion device.

7. Patients receiving continuous subcutaneous insulin infusion therapy must have replaceable insulin with them to prevent interruption of medication due to damage to the insulin pump system.

Use and Handling Instructions:

This product is intended for subcutaneous injection or for use in insulin pumps for continuous subcutaneous insulin infusion therapy. This product may also be administered intravenously under the gross supervision of a physician.

INSULIN PUMP DELIVERY: The inner surface of the tubing should be made of polyethylene or polyolefin that has been certified to meet the requirements of an insulin pump. A variable dose of insulin may be adsorbed to the reservoir, although it remains stable at all times.

Intravenous administration: A polypropylene infusion kit of 100 U/ml of menthol insulin with 0.9% sodium chloride, 5% or 10% dextrose, and 40 mmol/l potassium chloride is used to prepare an infusion fluid with a concentration of 0.05 U/ml to 1.0 U/ml, which is stable for 24 hours at room temperature. The patient's blood glucose level should be monitored concurrently with the insulin infusion.

If a patient is being treated with both this product and another insulin refill, two separate Novo Nordisk insulin injection systems should be used, each for the injection of a different type of insulin.

This product is intended for one person only.

Before using this product

Ø Check the label of this product and make sure it contains the correct type of insulin.

Ø Inspect this product, including the rubber plunger, before use. Do not use if the refill has been damaged or if there is a gap between the rubber piston and the white barcode band. Ø Read the insulin injection system instructions carefully for further guidance.

Ø Use a medical swab to sterilize the rubber membrane.

Circumstances in which this product must not be used

Ø If this product or the instrument containing it is dropped, damaged or crushed, it may be destroyed and leakage may occur.

Ø If the product is improperly stored or frozen.

Ø If the Mentholated Insulin Injection does not appear as a clear colorless liquid.

The injection site should be rotated in the injection area to avoid lumps. The best injection sites are the front of the waist (abdomen); buttocks; anterior thighs or upper arms. Subcutaneous administration into the abdominal wall works more quickly.

How to use this product

▲This product is given subcutaneously. Patients should inject using instructions from their doctor or diabetes nurse practitioner and injection techniques described in the Insulin Injection System User Manual.

▲The needle should remain under the skin for at least 6 seconds after injection to ensure that all of the medicine is injected into the body.

▲The needle must be removed after each injection. Otherwise, medicine will leak out of the needle when the temperature changes.

Precautions:

Hyperglycemia may be caused when insulin injections are given in insufficient doses or when treatment is interrupted, and is especially likely to occur in patients with type 1 diabetes. The first symptoms of hyperglycemia usually appear gradually over about a few hours or days. Symptoms include nausea, vomiting, drowsiness, dry red skin, dry mouth and frequent urination, thirst, loss of appetite, and an acetone odor on the breath. In patients with type 1 diabetes, the development of hyperglycemia, if left untreated, can eventually lead to the potentially fatal diabetic ketoacidosis.

Patients with significant improvement in glycemic control (e.g., those receiving intensive insulin therapy) will have altered prodromal symptoms of hypoglycemia and should be alerted to this.

If hypoglycemic symptoms occur, they will occur earlier after injection of this product than with soluble human insulin because of the rapid onset pharmacodynamic profile of insulin analogs.

Injections of this product should be timed closely to meal times, i.e., immediately before meals. The rapid onset of action of this product makes it important to consider both the patient's comorbidities and whether co-administration of the drug will delay the absorption of food.

In the presence of other concomitant illnesses (especially infections), the patient's insulin requirement is usually increased.

In renal or hepatic insufficiency, the patient's insulin requirement is usually reduced.

When a patient is switched to a different type of insulin preparation, the precursor symptoms of hypoglycemia may be different or less pronounced than with the original insulin preparation. The process of switching patients to a different type or brand of insulin preparation must be done under close medical supervision. Changes in any of the following may result in a change in dosage: drug concentration, brand, type, species (animal insulin, human insulin, human insulin analog), and/or manufacturing process. Patients switching to this product should have the dose or number of doses adjusted at the time of the first administration, or within a few weeks or months of starting treatment, if such adjustments are necessary.

Hypoglycemia can result if meals are skipped or unplanned, intense physical activity is undertaken.

With concomitant other illnesses (especially infections), the patient's insulin requirements are usually increased.

This product contains m-cresol, which may cause allergic reactions in isolated cases.

Use with caution in athletes.

Effects on driving and ability to operate machinery:

Hypoglycemia may impair the patient's ability to concentrate and react. Impairment of these abilities can be dangerous (e.g., during driving a car and operating machinery).

Patients should be specifically warned to take care to avoid hypoglycemic reactions while driving, especially in patients with poor or absent hypoglycemic precursor symptoms and those who have had frequent hypoglycemic episodes in the past. In these cases, the patient's ability to operate safely should be the first consideration.

Storage:

Unused product should be refrigerated in a refrigerator at 2-8°C, not frozen.

Keep in the original box to protect from light.

Do not store the product being used in the refrigerator; it may be stored at room temperature (not exceeding 30°C) for up to 4 weeks.

Store carefully out of the reach of children.

The expiration date is stated on the box and label; do not use expired medication.

Note that the needle must be removed after each injection. Otherwise, the medicine will leak out of the needle when the temperature changes.

The information is from the Internet and is for reference only.